A UK trial found continuous glucose monitoring improved HbA1c and time in range for adults with type 2 diabetes using basal insulin. Dexcom is also awaiting a Medicare decision on broader CGM coverage for non-insulin users.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
MannKind Corporation has enrolled the first pediatric patient in its INHALE-1ST trial evaluating Afrezza inhaled insulin in children with type 1 diabetes. The FDA is reviewing a supplemental Biologics License Application with a decision expected by May 29, 2026.
Novo Nordisk confronts rising generic threats to its semaglutide-based drugs while navigating FDA scrutiny and legal challenges. The company advances oral semaglutide into pediatric diabetes care as competitors prepare to launch imitations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07224321 |
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes |
RECRUITING | PHASE2 |
| NCT06280703 |
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) |
RECRUITING | PHASE1 |
| NCT06236672 |
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease |
COMPLETED | |
| NCT05904743 |
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
COMPLETED | PHASE4 |
| NCT05161429 |
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes |
UNKNOWN | |
| NCT04974528 |
Afrezza® INHALE-1 Study in Pediatrics |
COMPLETED | PHASE3 |
| NCT04864977 |
A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes |
WITHDRAWN | PHASE4 |
| NCT04809311 |
Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments |
COMPLETED | |
| NCT02987348 |
Clinical Outcomes of Exenatide Versus Basal Insulin |
COMPLETED | |
| NCT02974244 |
Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins |
COMPLETED |
